Behavioural Addiction and Genetics in Parkinson's Disease

Parkinson Disease Clinical Trial

— BADGE-PD  

Official title:

Behavioural Addiction and Genetics in Parkinson's Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02319395
• Other study ID #: P100133
• Status: Completed
• Phase: N/A
• First received: September 29, 2014
• Last updated: January 24, 2017
• Start date: November 2011
• Est. completion date: March 2016

Study information

• Verified date: March 2016
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The " Behavioural Addiction and Genetics in Parkinson's Disease " study (BADGE-PD) is a national (France), multicenter, genetic association, case-control study to identify genetic factors associated with behavioural addiction (or Impulse Control Disorders, ICD) related to dopamine agonists treatment in Parkinson's disease (PD). Polymorphisms of candidate genes supposed to be involved in this adverse effect will be compared in 200 PD patients with ICD (n=200) and 200 matched PD patients without ICD (n=200).

Description:

Objective: To identify susceptibility genes to impulse control disorders in Parkinson's Disease.

Study design: Genetic association study.

Primary objective:

To identify the susceptibility genes in behavior addiction in Parkinson's Disease

Secondary endpoints:

• To compare the clinical, neurological and psychiatric features of parkinsonian patients with behavior addiction compared to the control population. In case of differences between these groups, interaction will be studied with genetic factors

• Identify a psychometric profile from the TCI-R scale corresponding to the "hyperdopaminergic" subjects with AC personality

Patient selection:

Cases: patients with Parkinson's disease (PD) and impulse control disorder (ICD) as defined by a score greater than or equal to 2 or 3 scores greater than or equal to 2 at the "Evaluation Comportementale de la Maladie de Parkinson" scale (ECMP, Ardouin et al. 2009) for hyperdopaminergic items.

Controls: PD patients without impulse control disorder (ICD) as defined by a score of 0 or 1 at each hyperdopaminergic items AND no more than 2 items with a score of 1. Controls must have been treated with at least 300 mg of Levodopa equivalent daily dose for more than 12 months. Controls will be matched for sex, age, and age at onset of PD.

Number of subjects: 200 cases and 200 controls.

Clinical assessment: motor score (UPDRS), neuropsychological assessment, diagnostic criteria for addiction and ICD (MINI), self-administered psychometric questionnaire (TCI-R), treatment history, ICD history.

Genetic analysis: A blood sample will be taken for extraction and storage of DNA (DNA bank and Pitie-Salpetriere cells). Candidate genes* and polymorphisms will be selected from the literature data (receptors, transporters and metabolizing enzymes monoamine) and the molecular signature induced by L-DOPA in the striatum of a mice model of PD.

Statistical analysis:

A two-step analysis will be performed. For the first step, a training set (36% of subjects) will be analyzed with a logistic regression model considering an additive genetic effect. For the second step, the top 27% of the more significant genetic markers will be analyzed by using the left over replication set (64% of patients). Finally, a pooled analysis will be performed.

Sample Size: 200 patients per group to study 50 candidate markers with a power of 83% for genotype effect of 2.0, an additive genetic model, each allele frequency of 0.5.

• candidate genes list:

20 genes from the literature : DRD1, ANKK1, DRD2, DRD3, DRD4, DAT1, MAOA, COMT, HTR2A, HTR1B, TPH1, TPH2, 5HTT, GRIN2B, DBH, SCL6A2, BDNF, OPMR1, OPRK1, PDYN 8 genes from the experimentation: FosB, Arc, Nptx2, Ccrn4l, Car12, C8b, Mocs1, Mef2c

Recruitment information / eligibility

• Status: Completed
• Enrollment: 332
• Est. completion date: March 2016
• Est. primary completion date: November 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria :

Case Group

1. Age upper or equal to 30 years

2. Caucasian European (2 parents and 4 grandparents born in Europe)

3. Parkinson's disease according to the criteria of UKPDSBB

4. With a behavioral addiction defined as:

• A score greater than or equal to 2 or 3 scores greater than or equal to 2 at hyperdopaminergic following items of Ardouin's scale (ECMP): eating behaviors, creativity, hobbyism, risk-taking behaviors, compulsive shopping, pathological gambling, hypersexuality, cyber-addiction, and Punding.

• Onset under dopamine agonist or under L-DOPA

• Present at the inclusion visit

• OR in the past (<6 years). For these patients, the scale of Ardouin must have been passed at the time of behavior trouble or within 3 months after its disappearance.

5. Affiliation to a social security

6. Signature of the consent form

Control Group

1. Age upper or equal to 30 years

2. Caucasian European (2 parents and 4 grandparents born in Europe)

3. Parkinson's disease according to the criteria of UKPDSBB

4. Time evolution of the disease than or equal to 5 years

5. Having taken during its evolution a dopamine agonist dose at least equivalent to 300 mg of L-DOPA for at least 12 months.

6. Not having behavioral addiction

• Not current, defined as a score of 0 or 1 and at most two items with a score of 1 on all items above and addiction to L-DOPA.

• Neither passed, given authenticated by the semi-structured interview retrospective finding a score of 0 or 1 on all items hyperdopaminergic of Ardouin's scale (see above) AND no more than two items with a score of 1 and addiction to L-DOPA.

7. Affiliation to a social security

8. Signature of the consent form

Exclusion criteria :

Case Group

1. No Parkinson's disease or atypical parkinsonian syndrome

2. Taking neuroleptic except clozapine for patients with AC

3. Behavioral Addiction having started BEFORE taking the antiparkinsonian treatment

Control Group

1. No Parkinson's disease or atypical parkinsonian syndrome

2. Taking neuroleptic included clozapine for control patients

3. Behavioral Addiction having started BEFORE taking the antiparkinsonian treatment

4. Patient with guardianship, deprived of his liberty by judicial decision

Related Conditions & MeSH terms

• Behavior, Addictive
• Impulse Control Disorders
• Parkinson Disease

Intervention

Genetic:
• Blood Sampling and DNA collection
One blood sampling during the study. A small number (1 to 5) of markers type "tag SNPs" or "coding SNP" " (single nucleotide polymorphism, SNP) will be selected for each of the selected genes, for a total of 50 markers (representing 20 to 25 genes). Non-silent coding SNP, that may have a functional effect, will be included as a priority. Genotyping is carried out by the method of genotyping VeraCode Goldengate.

Locations

Country	Name	City	State
France	Groupe Hospitalier La Pitié Salpêtrière	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Allele frequency of 50 genetic markers (polymorphisms) will be compared between cases and controls.		baseline
Secondary	number of patients with a diagnostic of ICD according to the MINI		baseline
Secondary	Total UPDRS (Unified Parkinson's Disease Rating Scale) score		baseline
Secondary	Total score of the MMSE (Mini Mental State Examination)		baseline
Secondary	Sub scores at the temperament and Character Inventory (revised version, TCI-R)		baseline
Secondary	Number of subject in each group with personal or familial history of addiction		baseline